Point Estimate consideration in sample size estimate [Power / Sample Size]

posted by kimhuang – China, 2025-10-15 02:53 (257 d 12:05 ago) – Posting: # 24454
Views: 2,924

Dear Helmut,

Thank you very much for your response and kind reminder. I am still interested in the opinions of other experts. :-D:-D:-D

I still have a concern: when using GMR = 1.1 for sample size estimation, the actual GMR is 1.13 and 90% confidence interval is still within the range of 0.8 – 1.25. If the GMR of other generic drugs is within the ±5% difference to the reference, will the FDA approve product marketing? Is there any risk of ANDA’s review? Is it possible to provide examples where GMR is < 0.9 or > 1.1 and the product still be approved by FDA or other regulator?

Best Regards!


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
220 visitors (0 registered, 220 guests [including 22 identified bots]).
Forum time: 14:59 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5